HillA, van der LugtJ, SawyerW, BoffitoM. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. AIDS, 2009; 23:2237–2245.
2.
ShuterJ, SarloJA, RodeRA, ZingmanBS. Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy. HIV Clin Trials, 2009; 10:135–142.
3.
VivianeL, HarriganR, BangsbergDR, HoggDR, GrossR, YipB, MontanerJ. The combined effect of moderm highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr, 2009; 50:529–536.
4.
ShiL, LiuJ, FonsecaV, WalkerP, KalsekarA, PawaskarM. Correlation between adherence rates measured by MEMS and self-reported questionnaires: A meta-analysis. Health Qual Life Outcomes, 2010; 8:99.
5.
SteinerJF, ProchazkaAV. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol, 1997; 50:105–116.
6.
SohlerNL, ColemanSM, CabralH, Naar-KingS, Tobias CO. Cunningham Ch. AIDS Patient Care STDs, 2009; 23:837–843.
7.
GrossR, YipB, Lo ReV3rd, WoodE, AlexanderCS, HarriganPR, BangsbergDR, MontanerJS, HoggRS. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis, 2006; 194:1108–1114.
